Objective:To describe the effect of distraction lengthening to correct nail deformity in unilateral congenital brachydactyly type D (BDD).Methods:Patients with unilateral BDD who were treated by distraction lengthening between January 2020 and December 2021 in the Department of Plastic and Reconstructive Surgery of Shanghai 9th People’s Hospital were retrospectively reviewed. A transverse osteotomy was applied on the middle diaphysis of distal phalanx, and one pin was inserted percutaneously on both sides of the osteotomy site, then a mini external fixator was installed. Distraction lengthening was performed with a slow and sustained procedure. The aesthetic and functional results were compared preoperatively and postoperatively. Patient satisfaction questionnaires were recorded.Results:35 patients were enrolled, including 12 males and 23 females, with a mean age of 29.5 years. 17 thumbs were left and 18 thumbs were right. The time for distraction lengthening was 10-17 days, and the mean time was 12.3 days. The total time for external fixator maintenance was 55-70 days, with a mean time of 61.4 days. The mean follow-up was 18.6 months. The mean thumbnail length was increased from (9.2±0.6) mm to (14.2±0.4) mm [lengthening ratio, (54.4±7.5)%] after distraction lengthening ( P<0.05). The ratio of nail length to width changed from 0.63±0.05 to 1.05±0.04 [increase ratio, (68.2±10.5)%, P<0.05], which was equal to the normal value (1.07±0.03) ( P>0.05). Meanwhile, the distal thumb length increased from (22.6±0.7) mm to (29.6±1.0) mm ( P<0.05), with a mean increase of (6.9±1.0) mm, and the increase ratio was (30.8±4.8)%. The ratio of nail length to distal thumb length changed from 0.41±0.03 to 0.51±0.02 [increase ratio, (23.6±8.3) %, P<0.05]. The thumb function was not significantly influenced ( P>0.05). 33 patients (94.3%) were very satisfied with the results. Conclusion:Short nail deformity in BDD can be corrected by distraction lengthening with a good aesthetic appearance and without functional impairment.

Objective:To describe the effect of distraction lengthening to correct nail deformity in unilateral congenital brachydactyly type D (BDD).Methods:Patients with unilateral BDD who were treated by distraction lengthening between January 2020 and December 2021 in the Department of Plastic and Reconstructive Surgery of Shanghai 9th People’s Hospital were retrospectively reviewed. A transverse osteotomy was applied on the middle diaphysis of distal phalanx, and one pin was inserted percutaneously on both sides of the osteotomy site, then a mini external fixator was installed. Distraction lengthening was performed with a slow and sustained procedure. The aesthetic and functional results were compared preoperatively and postoperatively. Patient satisfaction questionnaires were recorded.Results:35 patients were enrolled, including 12 males and 23 females, with a mean age of 29.5 years. 17 thumbs were left and 18 thumbs were right. The time for distraction lengthening was 10-17 days, and the mean time was 12.3 days. The total time for external fixator maintenance was 55-70 days, with a mean time of 61.4 days. The mean follow-up was 18.6 months. The mean thumbnail length was increased from (9.2±0.6) mm to (14.2±0.4) mm [lengthening ratio, (54.4±7.5)%] after distraction lengthening ( P<0.05). The ratio of nail length to width changed from 0.63±0.05 to 1.05±0.04 [increase ratio, (68.2±10.5)%, P<0.05], which was equal to the normal value (1.07±0.03) ( P>0.05). Meanwhile, the distal thumb length increased from (22.6±0.7) mm to (29.6±1.0) mm ( P<0.05), with a mean increase of (6.9±1.0) mm, and the increase ratio was (30.8±4.8)%. The ratio of nail length to distal thumb length changed from 0.41±0.03 to 0.51±0.02 [increase ratio, (23.6±8.3) %, P<0.05]. The thumb function was not significantly influenced ( P>0.05). 33 patients (94.3%) were very satisfied with the results. Conclusion:Short nail deformity in BDD can be corrected by distraction lengthening with a good aesthetic appearance and without functional impairment.

Objective To test the efficacy of behavioral intervention and rosuvastatin alone and in combination for antipsychotic-induced metabolic syndrome. Methods One hundred and twenty eight schizophrenic patients who met the diagnostic criteria for metabolic syndrome were randomly divided into four groups:behavioral intervention plus rosuvastatin (5 mg/d), rosuvastatin (5 mg/d), behavioral intervention, placebo. And four groups all finished 12-week individual treatments. The total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, fasting blood-glucose, blood pressure, height and body weight were measured at baseline and at weeks 4, 8, and 12. In addition, the body mass index (BMI) were calculated. All patients were assessed with the Schizophrenia Quality of Life Scale (SQLS), Montreal Cognitive Assessment Scale (MoCA), Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Syndrome Scale (TESS) at baseline and at week 12 to evaluate the schizophrenia quality of life, cognitive function, efficacy and side effects. Results (1) After treatment, the triglyceride, glucose, body fat index, systolic pressure levels decreased significantly in the behavioral intervention plus rosuvastatin (t=6.37, 3.56, 5.26, 3.71, P<0.05), the high density lipoprotein cholesterol levels increased significantly (t=- 3.89). The triglyceride, glucose, body fat index, systolic pressure levels decreased significantly in the rosuvastatin (t=3.19, 8.44, 2.76, 3.86, P<0.05), the high density lipoprotein cholesterol levels increased significantly (t=-1.80, P<0.05). The triglyceride, glucose, body fat index, systolic pressure levels decreased significantly (t=2.94, 3.10, 3.50, 3.38, P<0.05), the high density lipoprotein cholesterol levels increased significantly (t=- 3.06, P<0.05) in the behavioral intervention group. (2) After treatment, the triglycerides (95%CI:-0.249--0.091, -0.308--0.152, all P<0.05) and blood glucose (95%CI:-0.081--0.059,-0.051--0.029, P<0.05) decreased was the highest in the behavior intervention plus rosuvastatin, followed by the rosuvastatin intervention. The cholesterol (95%CI:-1.538--0.696,-1.391--0.535, P<0.05) and body mass index (95%CI:-0.677--0.024,-0.844--0.562, P<0.05) decreased had no difference in the behavior intervention plus rosuvastatin and rosuvastatin,significantly greater than the behavior intervention. (3) At week 12, the score of SQLS decreased significantly in the behavior intervention plus rosuvastatin (t=7.99), rosuvastatin (t=6.25), behavior intervention (t=10.98), and increased significantly in the placebo(t=-3.10). The score of MoCA increased significantly in the behavior intervention plus rosuvastatin(t=-8.75),all P<0.05. Conclusions Behavioral intervention and rosuvastatin alone and in combination have efficacy for antipsychotic-induced metabolic syndrome, in which the combination therapy shows the best effect on improving MS and cognitive function.

Objective To test the efficacy of behavioral intervention and rosuvastatin alone and in combination for antipsychotic-induced metabolic syndrome. Methods One hundred and twenty eight schizophrenic patients who met the diagnostic criteria for metabolic syndrome were randomly divided into four groups:behavioral intervention plus rosuvastatin (5 mg/d), rosuvastatin (5 mg/d), behavioral intervention, placebo. And four groups all finished 12-week individual treatments. The total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, fasting blood-glucose, blood pressure, height and body weight were measured at baseline and at weeks 4, 8, and 12. In addition, the body mass index (BMI) were calculated. All patients were assessed with the Schizophrenia Quality of Life Scale (SQLS), Montreal Cognitive Assessment Scale (MoCA), Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Syndrome Scale (TESS) at baseline and at week 12 to evaluate the schizophrenia quality of life, cognitive function, efficacy and side effects. Results (1) After treatment, the triglyceride, glucose, body fat index, systolic pressure levels decreased significantly in the behavioral intervention plus rosuvastatin (t=6.37, 3.56, 5.26, 3.71, P<0.05), the high density lipoprotein cholesterol levels increased significantly (t=- 3.89). The triglyceride, glucose, body fat index, systolic pressure levels decreased significantly in the rosuvastatin (t=3.19, 8.44, 2.76, 3.86, P<0.05), the high density lipoprotein cholesterol levels increased significantly (t=-1.80, P<0.05). The triglyceride, glucose, body fat index, systolic pressure levels decreased significantly (t=2.94, 3.10, 3.50, 3.38, P<0.05), the high density lipoprotein cholesterol levels increased significantly (t=- 3.06, P<0.05) in the behavioral intervention group. (2) After treatment, the triglycerides (95%CI:-0.249--0.091, -0.308--0.152, all P<0.05) and blood glucose (95%CI:-0.081--0.059,-0.051--0.029, P<0.05) decreased was the highest in the behavior intervention plus rosuvastatin, followed by the rosuvastatin intervention. The cholesterol (95%CI:-1.538--0.696,-1.391--0.535, P<0.05) and body mass index (95%CI:-0.677--0.024,-0.844--0.562, P<0.05) decreased had no difference in the behavior intervention plus rosuvastatin and rosuvastatin,significantly greater than the behavior intervention. (3) At week 12, the score of SQLS decreased significantly in the behavior intervention plus rosuvastatin (t=7.99), rosuvastatin (t=6.25), behavior intervention (t=10.98), and increased significantly in the placebo(t=-3.10). The score of MoCA increased significantly in the behavior intervention plus rosuvastatin(t=-8.75),all P<0.05. Conclusions Behavioral intervention and rosuvastatin alone and in combination have efficacy for antipsychotic-induced metabolic syndrome, in which the combination therapy shows the best effect on improving MS and cognitive function.

The present situation of medical equipment department was introduced from the aspects of function, management and personnel. The influencing factors were explored for medical equipment department. Some suggestions were put forward including the national progress in medical equipment management, technician qualification certification, training and examination, title promotion and etc. Medical equipment department may stride forward with the development of all conditions.

AIM: To probe into the method of field processed products of Paeonia suffruticosa Andr. and inspect its quality. METHODS: Through field processed investigation alcohol-macerated extracts and paenol content compared among the smoked, de-epidermis, drying and direct drying in the sun. RESULTS: Paeonia suffruticosa Andr. with the epidermis is better than others. CONCLUSION: The method of integrating field cutting crude drugs into pieces with processing of Paeonia suffruticosa Andr. has feasible standardization and industrial benefits.